1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. HIV Integrase

HIV Integrase

HIV integrase is one of the three key enzymes of the pol gene of HIV. HIV integrase catalyzes the insertion into the genome of the infected human cell of viral DNA produced by the retrotranscription process. This unique step in the virus life cycle provides a variety of points for intervention and hence is an attractive target for the development of new therapeutics for the treatment of AIDS. HIV integrase includes HIV-1 and HIV-2 integrases.

HIV-1 integrase is a 32-kDa enzyme that carries out DNA integration in a two-step reaction. In the first step, called 3′ processing, two nucleotides are removed from each 3′ end of the viral DNA made by reverse transcription. In the next step, called DNA strand transfer, a pair of transesterification reactions integrates the ends of the viral DNA into the host genome. Integrase is comprised of three structurally and functionally distinct domains, and all three domains are required for each step of the integration reaction.

HIV Integrase Related Products (73):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-17605S1
    Bictegravir-d5
    Inhibitor
    Bictegravir-d5 is deuterated labeled Bictegravir (HY-17605). Bictegravir (GS-9883) is a potent inhibitor of HIV-1 integrase with an IC50 of 7.5 nM.
    Bictegravir-d<sub>5</sub>
  • HY-15592R
    Cabotegravir (Standard)
    Inhibitor
    Cabotegravir (Standard) is the analytical standard of Cabotegravir. This product is intended for research and analytical applications. Cabotegravir (GSK-1265744) is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC50 values of 2.5 nM, 0.41 μM and 0.81 μM for HIVADA, OAT3 and OAT1, respectively. Cabotegravir is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir can be used to research AIDS.
    Cabotegravir (Standard)
  • HY-14740S1
    Elvitegravir-d6
    Inhibitor
    Elvitegravir-d6 (GS-9137-d6) is deuterium labeled Elvitegravir. Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively.
    Elvitegravir-d<sub>6</sub>
  • HY-W103287
    2-Hydroxyisoquinoline-1,3(2H,4H)-dione
    Inhibitor
    Hydroxyisoquinoline-1,3(2H,4H)-dione (compound 6a) is a HIV-1 integrase (IN) and HIV-1 reverse transcriptase (RT) ribonuclease H (RNase H) inhibitor with an IC50 value of 6.32, 5.9 µM, respectively.
    2-Hydroxyisoquinoline-1,3(2H,4H)-dione
  • HY-10353AS2
    Raltegravir-d4 potassium
    Inhibitor
    Raltegravir-d4 (potassium) (MK 0518-d4 (potassium)) is deuterium labeled Raltegravir (potassium). Raltegravir (MK 0518) potassium is a potent integrase (IN) inhibitor, used to treat HIV infection.
    Raltegravir-d<sub>4</sub> potassium
  • HY-14740R
    Elvitegravir (Standard)
    Inhibitor
    Elvitegravir (Standard) is the analytical standard of Elvitegravir. This product is intended for research and analytical applications. Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively.
    Elvitegravir (Standard)
  • HY-10353AR
    Raltegravir (potassium) (Standard)
    Inhibitor
    Raltegravir (potassium) (Standard) is the analytical standard of Raltegravir (potassium). This product is intended for research and analytical applications. Raltegravir (MK 0518) potassium is a potent integrase (IN) inhibitor, used to treat HIV infection.
    Raltegravir (potassium) (Standard)
  • HY-17605S4
    Bictegravir-d7
    Inhibitor
    Bictegravir-d7 (GS-9883-d7) is deuterium labeled Bictegravir. Bictegravir (GS-9883) is a potent inhibitor of HIV-1 integrase with an IC50 of 7.5 nM.
    Bictegravir-d<sub>7</sub>
  • HY-14740S2
    Elvitegravir-13C6
    Inhibitor
    Elvitegravir-13C6 (GS-9137-13C6) is 13C labeled Elvitegravir. Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively.
    Elvitegravir-<sup>13</sup>C<sub>6</sub>
  • HY-16907B
    GSK-364735 sodium
    Inhibitor
    GSK-364735 sodium (S/GSK-364735 sodium) is the sodium salt form of GSK-364735 (HY-16907). GSK-364735 sodium is an antiretroviral, that inhibits the integrase of human immunodeficiency virus type 1 (HIV-1) with an IC50 of 7.8 nM.
    GSK-364735 sodium
  • HY-13238R
    Dolutegravir (Standard)
    Inhibitor
    Dolutegravir (Standard) is the analytical standard of Dolutegravir. This product is intended for research and analytical applications. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM).
    Dolutegravir (Standard)
  • HY-17605R
    Bictegravir (Standard)
    Inhibitor
    Bictegravir (Standard) is the analytical standard of Bictegravir. This product is intended for research and analytical applications. Bictegravir (GS-9883) is a potent inhibitor of HIV-1 integrase with an IC50 of 7.5 nM.
    Bictegravir (Standard)
  • HY-W749636
    N-De-2,4-difluorobenzyl dolutegravir
    Inhibitor
    N-De-2,4-difluorobenzyl dolutegravir is a metabolite of Dolutegravir (HY-13238). Dolutegravir is a HIV integrase inhibitor inhibitor.
    N-De-2,4-difluorobenzyl dolutegravir